Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025
Company Drug

ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM

Fineline Cube Jun 7, 2023

Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...

Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA

Fineline Cube Jun 7, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...

Company Deals Digital

Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare

Fineline Cube Jun 7, 2023

China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...

Company Drug

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia

Fineline Cube Jun 7, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Drug

Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma

Fineline Cube Jun 7, 2023

Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...

Company Medical Device

Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge

Fineline Cube Jun 7, 2023

China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...

Company Deals

Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion

Fineline Cube Jun 6, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...

Company Drug

CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023

Fineline Cube Jun 6, 2023

China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study

Fineline Cube Jun 6, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...

Company Drug

Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting

Fineline Cube Jun 6, 2023

A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...

Company Deals

Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production

Fineline Cube Jun 6, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital...

Company Deals

Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders

Fineline Cube Jun 6, 2023

Private equity firm Longreach Group, which specializes in the Asian market, is in the process...

Company Drug

Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting

Fineline Cube Jun 6, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline...

Company Drug

Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma

Fineline Cube Jun 5, 2023

Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received...

Company Medical Device

NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional...

Company Medical Device

NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System

Fineline Cube Jun 5, 2023

The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin...

Company Deals

HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development

Fineline Cube Jun 5, 2023

China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on...

Company Deals

Shanghai Duoning Biotechnology Partners with Wuhan Kaide Jinuo for Gene Therapy R&D

Fineline Cube Jun 5, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm...

Company Drug

Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH

Fineline Cube Jun 5, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...

Posts pagination

1 … 454 455 456 … 602

Recent updates

  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.